KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $7.4 billion.

  • Jazz Pharmaceuticals' Total Liabilities fell 850.0% to $7.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 billion, marking a year-over-year decrease of 850.0%. This contributed to the annual value of $7.9 billion for FY2024, which is 342.38% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Total Liabilities stood at $7.4 billion, which was down 850.0% from $7.2 billion recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Total Liabilities high stood at $9.1 billion for Q2 2021, and its period low was $3.0 billion during Q1 2021.
  • Moreover, its 5-year median value for Total Liabilities was $7.7 billion (2023), whereas its average is $7.6 billion.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Total Liabilities surged by 21051.1% in 2021, and later plummeted by 1191.6% in 2022.
  • Jazz Pharmaceuticals' Total Liabilities (Quarter) stood at $8.3 billion in 2021, then fell by 7.01% to $7.7 billion in 2022, then decreased by 1.2% to $7.7 billion in 2023, then grew by 3.42% to $7.9 billion in 2024, then decreased by 6.58% to $7.4 billion in 2025.
  • Its Total Liabilities stands at $7.4 billion for Q3 2025, versus $7.2 billion for Q2 2025 and $7.4 billion for Q1 2025.